{
    "nct_id": "NCT04917796",
    "official_title": "A Randomized Phase III Clinical Trial of Acupuncture for Chemotherapy-induced Peripheral Neuropathy Treatment (ACT)",
    "inclusion_criteria": "* English-proficient men and women aged ≥18 years\n* Free of oncologic disease by clinical examination and history\n* Completed neurotoxic chemotherapy such as platinum agents, taxanes, vinca alkaloids, and bortezomib at least three months prior to enrollment\n* Diagnosis of CIPN based on symptom history, loss of deep tendon reflexes, or the presence of symmetrical stocking-glove pain, numbness, or paresthesia73\n* Grade ≥1 sensory pain based on the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0\n* Self-reported moderate to severe CIPN pain, as defined by a score of 4 or greater on the BPI-SF average pain item over the past week\n* On a stable regimen (no change in the past three months) if taking anti-neuropathy or other pain medications\n* Willing to adhere to requirement that no new pain medication be taken throughout the first 12 weeks of the study period\n* Willing to adhere to all study-related procedures, including randomization to one of the two possible acupuncture treatments\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients with a pacemaker or other electronically charged medical device\n* Use of acupuncture for symptom management within the past 12 months",
    "miscellaneous_criteria": ""
}